- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00005085
Rebeccamycin Analog in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer
A Phase II Study of Rebeccamycin Analogue NSC 655649 in Patients With Metastatic Colorectal Cancer (IMT Codes 23988, 23989, 23993)
Studieöversikt
Detaljerad beskrivning
OBJECTIVES:
I. Determine the objective response rate of patients with metastatic or locally recurrent colorectal cancer treated with rebeccamycin analogue.
II. Determine the toxicity of this regimen in this patient population. III. Determine the effect of this regimen on progression-free and overall survival in these patients.
OUTLINE: This is a multicenter study.
Patients receive rebeccamycin analogue IV once on day 1. Treatment repeats every 21 days for a maximum of 12 courses in the absence of unacceptable toxicity or disease progression. Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30342
- Atlanta Cancer Care
-
-
New York
-
Bronx, New York, Förenta staterna, 10461
- Albert Einstein Comprehensive Cancer Center
-
Valhalla, New York, Förenta staterna, 10595
- New York Medical College
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed metastatic or locally recurrent adenocarcinoma of the colon or rectum
- No curable stage of disease
- At least 1 unidimensionally measurable lesion
- At 20 mm by conventional techniques OR at least 10 mm by spiral CT scan
- No tumor lesions in previously irradiated area except clearly measurable lesion documented histologically to be consistent with recurrent tumor in previously irradiated bed within pelvis
The following are considered nonmeasurable disease:
- Bone lesions Leptomeningeal disease
- Ascites
- Pleural/pericardial effusion
- Inflammatory breast disease
- Lymphangitis cutis/pulmonis
- Abdominal masses not confirmed and followed by imaging techniques
- Cystic lesions
- No known brain metastases
PATIENT CHARACTERISTICS:
- Age: 18 and over
- Performance status: ECOG 0-2 OR Karnofsky 60-100%
- Life expectancy: More than 12 weeks
- WBC at least 3,000/mm3
- Absolute neutrophil count at least 1,500/mm3
- Platelet count at least 100,000/mm3
- Bilirubin normal
- AST/ALT no greater than 2.5 times upper limit of normal
- Creatinine normal OR creatinine clearance at least 60 mL/min
- No symptomatic congestive heart failure
- No unstable angina pectoris
- No cardiac arrhythmia
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 6 months after study
- Eligible for placement of a central venous catheter
- No prior allergic reactions attributed to compounds of similar chemical or biologic composition to rebeccamycin analogue
- No other uncontrolled concurrent illness
- No ongoing or active infection
- No psychiatric illness or social situation that would preclude study compliance
PRIOR CONCURRENT THERAPY:
- No concurrent prophylactic growth factors (e.g., epoetin alfa) except for clinically defined indication (e.g., filgrastim (G-CSF) for febrile neutropenia)
- At least 4 weeks since prior chemotherapy (e.g., fluorouracil, oral fluoropyrimidines, irinotecan, or oxaliplatin) (6 weeks for nitrosoureas or mitomycin)
- No other concurrent chemotherapy
- No concurrent hormones except for clinically defined indication
- At least 4 weeks since prior radiotherapy (including to bony sites, whole pelvis, lung, liver, or spinal cord/brain) and recovered
- No prior total dose of radiotherapy more than 7,000 cGy
- No prior radiotherapy to 40% or more of total bone marrow
- No prior radiotherapy to only site of measurable disease
- No concurrent radiotherapy
- Recovered from prior therapy 1 prior adjuvant treatment allowed 1 prior treatment for advanced disease allowed
- At least 4 weeks since prior investigational agents
- No other concurrent investigational antineoplastic drugs
- No other concurrent investigational agents
- No concurrent commercial agents for colorectal cancer
- No concurrent combination antiretroviral therapy for HIV-positive patients
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Arm I
Patients receive rebeccamycin analogue IV once on day 1.
Treatment repeats every 21 days for a maximum of 12 courses in the absence of unacceptable toxicity or disease progression.
Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studiestol: Sridhar Mani, MD, Albert Einstein College of Medicine
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- CDR0000067695
- AECM-T99-0109
- NCI-T99-0109
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Kolorektal cancer
-
Incyte CorporationMerck Sharp & Dohme LLCAvslutadMelanom | Lymfom | Huvud- och halscancer | Magcancer | Äggstockscancer | Hepatocellulärt karcinom (HCC) | Lungcancer | Blåscancer | Endometriecancer | Fasta tumörer | Njurcellscancer (RCC) | Trippel negativ bröstcancer (TNBC) | UC (Urotelial cancer) | Microsatellite-instability (MSI) High Colorectal Cancer (CRC)Förenta staterna
Kliniska prövningar på becatecarin
-
National Cancer Institute (NCI)AvslutadSarkom | Lymfom | Ospecificerad fast tumör för barn, protokollspecifik | Tumörer i hjärnan och centrala nervsystemet | Neuroblastom | RetinoblastomFörenta staterna, Kanada, Puerto Rico, Australien, Nederländerna, Nya Zeeland, Schweiz
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)AvslutadNeuroblastomFörenta staterna
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)AvslutadNjurcancerFörenta staterna
-
Northwestern UniversityNational Cancer Institute (NCI)AvslutadÄggstockscancerFörenta staterna
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)Avslutad
-
National Cancer Institute (NCI)AvslutadSmåcellig lungcancer i ett omfattande stadium | Återkommande småcellig lungcancer | Småcellig lungcancer i begränsad stadiumFörenta staterna
-
National Cancer Institute (NCI)AvslutadManlig bröstcancer | Steg IV Bröstcancer | Steg IIIB Bröstcancer | Återkommande bröstcancerFörenta staterna
-
National Cancer Institute (NCI)AvslutadKronisk myelomonocytisk leukemi | Återkommande akut myeloid leukemi hos vuxna | Akut myeloid leukemi hos vuxna med 11q23 (MLL) avvikelser | Vuxen akut myeloid leukemi med Inv(16)(p13;q22) | Akut myeloid leukemi hos vuxna med t(16;16)(p13;q22) | Akut myeloid leukemi hos vuxna med t(8;21)(q22;q22) | Sekundär akut myeloid leukemi och andra villkorFörenta staterna
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)AvslutadLever cancer | Gallblåscancer | Extrahepatisk gallvägscancerFörenta staterna
-
National Cancer Institute (NCI)AvslutadLymfom | Tunntarmscancer | Ospecificerad fast tumör för vuxen, protokollspecifikFörenta staterna